ONCT Oncternal Therapeutics Inc.

3.04
+0.06  (+2%)
Previous Close 2.98
Open 3.04
Price To Book 4.47
Market Cap 46,792,826
Shares 15,392,377
Volume 23,980
Short Ratio
Av. Daily Volume 15,314
Stock charts supplied by TradingView

NewsSee all news

  1. Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with several

  2. Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting

    58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8

  3. Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results

    - Deep clinical responses reported for two of seven patients with relapsed/refractory Ewing sarcoma treated with the recommended Phase 2 dose of TK216 in ongoing Phase 1 clinical trial - 50% complete response rate

  4. Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results

  5. Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b expansion cohort data due 2H 2020.
TK216 and vincristine
Relapsed or refractory Ewing sarcoma
Phase 1b additional data 2H 2020.
Cirmtuzumab and paclitaxel
Breast cancer
Phase 1/2 update due at ASCO May 29, 2020.
Cirmtuzumab and ibrutinib (ASCO)
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)

Latest News

  1. Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with several

  2. Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting

    58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8

  3. Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results

    - Deep clinical responses reported for two of seven patients with relapsed/refractory Ewing sarcoma treated with the recommended Phase 2 dose of TK216 in ongoing Phase 1 clinical trial - 50% complete response rate

  4. Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results

  5. Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results

  6. Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results

    - Steady progress of clinical programs in four indications: MCL, Ewing sarcoma, breast cancer, and CLL - Cirmtuzumab in combination with ibrutinib demonstrated a 50% CR rate and 83% best ORR in patients with

  7. Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report its fourth quarter and full year 2019

  8. Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma

    50% (six of twelve) evaluable patients with relapsed/refractory MCL achieved complete responses (CR) in the dose-finding cohort of the ongoing Phase 1/2 clinical trial 83% best objective response rate (ORR) and 100%

  9. Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

    - Anti-ROR1 CAR-T cell therapy demonstrated expansion, persistence and anti-tumor activity in animal model of human leukemia Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company

  10. Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium

    - Four of seven evaluable patients with HER2-negative, metastatic or locally-advanced unresectable breast cancer achieved a partial response for an objective response rate of 57% - Cirmtuzumab in combination with

  11. Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma

    Dose-finding cohort demonstrated clinical activity and was generally well-tolerated TK216 has been granted Orphan Drug and Fast Track Designations for treatment of patients with relapsed/refractory Ewing

  12. Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting

    Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100% Cirmtuzumab has been very well tolerated in this trial Inhibition of ROR1

  13. Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that clinical data updates for cirmtuzumab, its

  14. Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief

  15. Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting

    Interim data from Phase 1 study in patients with Ewing sarcoma show TK216 has been generally well tolerated One of two patients at the current, highest TK216 exposure dose regimen has experienced a deep and sustained

  16. Oncternal Therapeutics to Present at Stifel Healthcare Conference

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief

  17. Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update

    Opened randomized, Phase 2 clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL and Phase 1b expansion cohort in patients with MCL, based on encouraging interim clinical results Reported

  18. Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 – an investigational targeted

  19. Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2019 financial results

  20. Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma

    Cirmtuzumab combination demonstrated clinical activity with complete responses in mantle cell lymphoma Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development

  21. Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children's Oncology Group Meeting

    Sustained objective response reported for patient with challenging pediatric cancer Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology

  22. Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of